UnitedHealth Group (NYSE: UNH) remains in focus ahead of the health insurance company's Q4 earnings scheduled for next week on January 27th. But for long-term investors, its upcoming earnings – even i... ...

Core Insights - American International Group, Inc. (AIG) has entered a strategic investment partnership with CVC, focusing on credit-related investments and private equity secondaries [1][4] - AIG plans to allocate nearly $3.5 billion over time through CVC-managed vehicles, with initial allocations starting in 2026 [2] - AIG will contribute approximately $1.5 billion as a cornerstone investor in CVC's private equity secondaries evergreen platform [2] - The partnership aims to enhance portfolio diversification, yield potential, and long-term returns for AIG [6] Investment Strategy - AIG will utilize separately managed accounts (SMAs) to gain exposure to diversified private and liquid credit assets, allocating around $2 billion [3] - The partnership is designed to be scalable and flexible, allowing for growth in allocations as performance and market conditions evolve [3] Market Context - This move reflects a trend among large insurers like AIG, shifting from traditional fixed-income investments to alternative assets for higher, more stable long-term returns [4] - The partnership signals confidence in private credit and secondaries as attractive asset classes in a higher-rate but uncertain economic environment [4] CVC's Position - CVC, with an AUM of €201 billion, benefits from this long-term partnership, enhancing its credibility and position in institutional capital markets [5] - The deal provides CVC with sizable, sticky capital, generating recurring fees and opportunities to scale its investment platforms [5] AIG's Financial Performance - AIG's trailing 12-month return on equity is 9.09%, below the industry average of 15.14% [6] - The Zacks Consensus Estimate for AIG's current-year earnings is $7.02 per share, indicating a 41.8% year-over-year growth, while revenue is estimated at $27.25 billion, signaling a 16.9% decline [7]

Total disclosed value for deals in 2025 “rose significantly” to $418.9 billion from $282.1 billion a year prior. This included 93 deals valued at more than $1 billion, which accounted for 81% of total deal value last year. By comparison, 54 such deals were announced in 2024.“Market conditions continued to challenge global financial services dealmaking in 2025 but did not dampen investment appetite within the sector. While the number of deals was only up marginally year-on-year, overall value was up 49%. Tra ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2025 investor letter. The firm anticipates stronger market volatility in the coming years and has moderated its enthusiasm. A copy of the letter can be downloaded here. The Wedgewood Composite returned -1.8% (net) in the fourth quarter compared to the S&P 500’s 2.7%, the Russell 1000 Growth Index’s 1.1%, and the Russell 1000 Value Index’s 3.8% returns. YTD, the Composite gained 4.3% compared to 17.9%, 18.6%, and 15.9% returns ...

Core Viewpoint - The article discusses the investment positions held by the author in specific companies, indicating a long position in LNC and SCRYY, which may suggest a positive outlook on these stocks [1]. Group 1 - The author expresses personal opinions on the stocks mentioned, emphasizing that the article is not influenced by external compensation [1]. - There is a clear distinction made that the author is not a licensed financial advisor, which may affect the interpretation of the information provided [2]. - The article highlights the importance of individual due diligence and research before making investment decisions, particularly in high-risk trading styles [2]. Group 2 - The article notes that past performance of stocks does not guarantee future results, indicating a cautious approach to investment recommendations [3]. - It clarifies that the views expressed may not represent the broader opinions of Seeking Alpha, suggesting a diversity of perspectives within the platform [3]. - The article emphasizes that the authors are third-party contributors, which may include both professional and individual investors without formal licensing [3].

1月17日下午，第十九届浙江金融投资论坛暨2025年浙江省国际金融学术年会在杭州举行。 本届论坛以"新阶段新理念新格局：金融高质量发展赋能浙江现代化先行"为主题，围绕财政的货币效应、数字货币兴起与全球金融体系、"十五五"浙江保 险业的高质量发展、金融助力浙江共同富裕示范区建设的机制与模式探索等议题，通过国内政策分析、国际趋势研判、实践探讨等形式进行分享交流。来 自浙江省相关部门领导、高校学者、研究院专家、金融机构及企业家代表、媒体等200余人参加。 浙江工商大学纪委书记胡金生，杭州海关原总工程师、浙江省国际金融学会执行会长余月其致开幕辞。 浙江财经大学浙商资本市场研究院执行院长、浙江省国际金融学会副秘书长武鑫做2025年度浙江省国际金融学会（联盟）工作总结。 围绕《数字货币兴起与全球金融体系重构》，复旦大学经济学院国际金融系主任、复旦大学国际金融研究中心主任杨长江从数字货币的多元化、功能化、 智能化、综合化等方面阐述了数字货币对全球金融体系带来的冲击，并提出了如何应对的建议。 上海财经大学金融学院教授、江苏省金融学会副会长卞志村，基于对财政影响货币运行的内在机理、实现路径以及提升政策组合效应的系统阐述与案例分 ...

Group 1 - The offer for Beazley is at a 56% premium to its closing price on Friday [1] - Shares in Beazley, a London-listed insurance company, surged following the announcement [1]

Group 1 - A beneficial owner has been increasing their stake in the insurance giant W.R. over the past week [1]

Core Insights - The Great Healthcare Plan aims to reduce prescription drug prices, lower insurance premiums, and increase transparency in the healthcare industry [1][11] - The plan shifts from corporate subsidies to direct payments to consumers, redistributing profit pools across the healthcare sector [2][10] Winners - Retail pharmacies, particularly chains like Walmart (WMT), will benefit from the proposal to sell more prescription drugs over-the-counter (OTC), driving foot traffic and sales [4] - Fintech healthcare companies, such as HealthEquity (HQY), will gain from direct-to-consumer subsidies, enhancing consumer choice and transparency [5] - Big pharmaceutical companies that have entered into Most-Favored-Nation (MFN) agreements, like Merck (MRK) and Johnson & Johnson (JNJ), will enjoy regulatory certainty and potential tariff relief [6] Losers - Pharmacy Benefit Managers (PBMs) are targeted by the plan, which aims to eliminate kickbacks, posing significant risks to companies like UnitedHealth Group (UNH) and Cigna (CI) [7] - Traditional health insurers, such as Centene (CNC) and Molina (MOH), face threats to their revenue models due to the plan's shift to direct payments to individuals [8] ETF Portfolio Recommendations - Investors are advised to consider ETFs that focus on diversified drugmakers and retail providers while avoiding those heavily invested in PBMs and traditional insurers [11] - Suggested ETFs include: - iShares U.S. Pharmaceuticals ETF (IHE) with $968 million in assets, focusing on 55 U.S. companies in the pharmaceutical sector [12] - State Street Consumer Staples Select Sector SPDR ETF (XLP) with $16.26 billion in assets, providing exposure to retail medicine providers [14] - iShares U.S. Medical Devices ETF (IHI) with $4.04 billion in assets, offering a defensive hedge against drug pricing battles [16] ETFs to Avoid - iShares U.S. Healthcare Providers ETF (IHF) with $750.5 million in assets, focusing on health insurance and specialized treatment providers [17] - State Street SPDR S&P Health Care Services ETF (XHS) with $101.4 million in assets, targeting healthcare service providers [19]

Swiss insurance company Zurich Insurance Group has raised its offer to buy rival speciality insurer Beazley to 1,280 pence per share in cash, it said on Monday, sending the British company's shares su... ...